CLGN logo

CLGN

Profile

Full Name

CollPlant Biotechnologies Ltd.

Ticker Symbol

CLGN

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

Israel

IPO

January 31, 2018

Indexes

Not included

Website

http://www.collplant.com

Employees

57

Key Details

Price

$2.42(-1.43%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$515.00K(-95.30% YoY)

Annual EPS

-$1.45(-133.87% YoY)

PE ratio

-

Next earnings date

May 29, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$2.42
CLGN price is $2.42

30-Day Relative Volume

0.16
CLGN 30-day relative volume is 0.16

Price Performance

Price Most recent change

-1.43%
CLGN price was down -1.43% on Apr 16, 2025

Price YTD change

-32.78%
CLGN price is down -32.78% since January 1st

Price 1-year change

-53.82%
CLGN price is down -53.82% year-on-year

Price 3-year change

-75.18%
CLGN price is down -75.18% over the past 3 years

Price Range

Price All-time high

$24.26
CLGN price is currently -90.02% below its historical high of $24.26

Price 3-year low

$2.20
CLGN price is currently +10.00% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$27.72M
CLGN market capitalization is $27.72 million

Market cap 3-year change

-74.36%
CLGN market capitalization is down -74.36% over the past 3 years

Market cap All-time high

$240.35M
CLGN market capitalization is currently -88.47% below its historical high of $240.35 million

Market cap sector rank

30.43%
CLGN market capitalization is higher than 30.43% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

0%
CLGN {parameterFullLabel} has remained unchanged year-on-year

Shares Outstanding 3-Year Change

+3.32%
CLGN shares outstanding is up +3.32% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.31
CLGN beta is 0.31

200-day SMA

$4.08
CLGN price is currently -40.63% below its 200-day simple moving average

50-day SMA

$3.08
CLGN price is currently -21.35% below its 50-day simple moving average

RSI

28.94
CLGN 14-day relative strength index is 28.94

Volume

0.16
CLGN 30-day relative volume is 0.16

ATR

$0.17
CLGN average true range is $0.17

10-day Historical Volatility

34.65%
CLGN 10-day historical volatility is 34.65%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$515.00K
CLGN annual revenue is $515.00 thousand

Revenue Analysts estimate

$42.42M
CLGN annual revenue is currently -98.79% lower than the consensus analysts' forecast

Revenue 1-year change

-95.3%
CLGN annual revenue is down -95.3% year-on-year

Revenue Sector rank

9.74%
CLGN annual revenue is higher than 9.74% of companies in Healthcare sector

EPS

EPS

-$1.45
CLGN annual earnings per share is -$1.45

EPS Analysts estimate

-
CLGN annual earnings per share consensus analysts' forecast is unknown

EPS 1-year change

-133.87%
CLGN annual earnings per share is down -133.87% year-on-year

EPS Sector rank

46.78%
CLGN annual earnings per share is higher than 46.78% of companies in Healthcare sector

Profit

Gross profit

-$1.11M
CLGN annual gross profit is -$1.11 million

Gross margin

-215.53%
CLGN annual gross profit margin is -215.53%

Operating profit

-$17.25M
CLGN annual operating income is -$17.25 million

Operating margin

-3349.71%
CLGN annual operating profit margin is -3349.71%

Net income

-$16.61M
CLGN annual net profit is -$16.61 million

Net margin

-3225.05%
CLGN annual net profit margin is -3225.05%

Expenses

Total expenses

$17.77M
CLGN annual total expenses is $17.77 million

Operating expenses

$16.14M
CLGN annual total operating expenses is $16.14 million

Cost of goods sold

$1.63M
CLGN annual cost of goods sold is $1.63 million

Selling, general & administrative expenses

$5.63M
CLGN annual SGA is $5.63 million

Depreciation and amortization

$1.04M
CLGN annual depreciation & amortization is $1.04 million

Interest expense

-
CLGN annual interest expense value is unknown

Income tax

-
CLGN annual income tax value is unknown

EBIT & EBITDA

EBIT

-$17.25M
CLGN annual earnings before interest & taxes is -$17.25 million

EBITDA

-$16.21M
CLGN annual EBITDA is -$16.21 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$18.71M
CLGN annual total assets is $18.71 million

Non current assets

$5.53M
CLGN annual long term assets is $5.53 million

Current assets

$13.18M
CLGN annual total current assets is $13.18 million

Cash and cash equivalents

$11.91M
CLGN annual cash & cash equivalents is $11.91 million

Accounts receivable

$150.00K
CLGN annual accounts receivable is $150.00 thousand

Inventory

$440.00K
CLGN annual inventory is $440.00 thousand

Liabilities

Total liabilities

$5.25M
CLGN annual total liabilities is $5.25 million

Long term liabilities

$2.27M
CLGN annual total long term liabilities is $2.27 million

Current liabilities

$2.97M
CLGN annual total current liabilities is $2.97 million

Accounts payable

$870.00K
CLGN annual accounts payable is $870.00 thousand

Debt

Total debt

$3.08M
CLGN annual total debt is $3.08 million

Total debt 1-year change

-2.47%
CLGN annual total debt is down -2.47% year-on-year

Long term debt

$2.27M
CLGN annual long term debt is $2.27 million

Short term debt

$806.00K
CLGN annual short term debt is $806.00 thousand

Equity & Capital

Shareholders equity

$13.46M
CLGN annual stockholders equity is $13.46 million

Book value

$13.46M
CLGN annual book value is $13.46 million

Retained earnings

-$113.35M
CLGN annual retained earnings is -$113.35 million

Working capital

$10.21M
CLGN annual working capital is $10.21 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$14.09M
CLGN annual cash flow from operations is -$14.09 million

Cash from operations 1-year change

-410.06%
CLGN annual cash flow from operations is down -410.06% year-on-year

Cash from investing

-$539.00K
CLGN annual cash flow from investing activities is -$539.00 thousand

Cash from investing 1-year change

+53.37%
CLGN annual cash flow from investing activities is up +53.37% year-on-year

Cash from financing

$9000.00
CLGN annual cash flow from financing activities is $9000.00

Cash from financing 1-year change

-99.19%
CLGN annual cash flow from financing activities is down -99.19% year-on-year

CAPEX

CAPEX

$483.00K
CLGN annual capital expenditures is $483.00 thousand

CAPEX 1-year change

-49.37%
CLGN annual capital expenditures is down -49.37% year-on-year

Free Cash Flow

Free cash flow

-$14.58M
CLGN annual free cash flow is -$14.58 million

Free cash flow 1-year change

-292.14%
CLGN annual free cash flow is down -292.14% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-215.53%
CLGN annual gross profit margin is -215.53%

Operating margin

-3349.71%
CLGN annual operating profit margin is -3349.71%

Net margin

-3225.05%
CLGN annual net profit margin is -3225.05%

ROA & ROE

ROA

-62.87%
CLGN annual return on assets is -62.87%

ROE

-79.46%
CLGN annual return on equity is -79.46%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
CLGN price to earnings ratio value is unknown

PE ratio Sector rank

-
CLGN price to earnings ratio is unknown

PB Ratio

PB ratio

2.06
CLGN price to book ratio is 2.06

PB ratio Sector rank

63.51%
CLGN price to book ratio is higher than 63.51% of companies in Healthcare sector

PS Ratio

PS ratio

53.83
CLGN price to sales ratio is 53.83

PS ratio Sector rank

92.69%
CLGN price to sales ratio is higher than 92.69% of companies in Healthcare sector

Enterprise value

Enterprise value

$18.89M
CLGN enterprise value is $18.89 million

Enterprise value Sector rank

31.13%
CLGN enterprise value is higher than 31.13% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.17
CLGN EV/EBITDA is -1.17

EV/EBITDA Sector rank

39.91%
CLGN EV/EBITDA is higher than 39.91% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

4.44
CLGN annual current ratio is 4.44

Quick ratio

4.29
CLGN annual quick ratio is 4.29

Leverage

Debt to equity

0.00
CLGN annual debt to equity ratio is 0.00

Interest coverage ratio

-
CLGN annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

3
CLGN piotroski f-score is 3

Altman Z-Score

-7.67
CLGN altman z-score is -7.67

Analyst ratings

Recent major analysts updates

Mar 27, 25 D. Boral Capital
Buy
Feb 12, 25 D. Boral Capital
Buy
Feb 4, 25 D. Boral Capital
Buy
Nov 29, 24 HC Wainwright & Co.
Buy
Nov 27, 24 D. Boral Capital
Buy
Aug 21, 24 HC Wainwright & Co.
Buy
Aug 20, 24 EF Hutton
Buy
Aug 5, 24 EF Hutton
Buy
May 30, 24 HC Wainwright & Co.
Buy
Apr 5, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

ALGS logo
Aligos Therapeutics (ALGS)
Grace Therapeutics (GRCE)
VYNE logo
VYNE Therapeutics (VYNE)
PYPD logo
PolyPid (PYPD)
FGEN logo
FibroGen (FGEN)
COCH logo
Envoy Medical (COCH)
AKTX logo
Akari Therapeutics (AKTX)
MLEC logo
Moolec Science SA (MLEC)
INTS logo
Intensity Therapeutics (INTS)
  • What is the ticker symbol for CollPlant Biotechnologies?
  • Does CollPlant Biotechnologies pay dividends?
  • What sector is CollPlant Biotechnologies in?
  • What industry is CollPlant Biotechnologies in?
  • What country is CollPlant Biotechnologies based in?
  • When did CollPlant Biotechnologies go public?
  • Is CollPlant Biotechnologies in the S&P 500?
  • Is CollPlant Biotechnologies in the NASDAQ 100?
  • Is CollPlant Biotechnologies in the Dow Jones?
  • When was CollPlant Biotechnologies's last earnings report?
  • When does CollPlant Biotechnologies report earnings?
  • Should I buy CollPlant Biotechnologies stock now?

What is the ticker symbol for CollPlant Biotechnologies?

The ticker symbol for CollPlant Biotechnologies is NASDAQ:CLGN

Does CollPlant Biotechnologies pay dividends?

No, CollPlant Biotechnologies does not pay dividends

What sector is CollPlant Biotechnologies in?

CollPlant Biotechnologies is in the Healthcare sector

What industry is CollPlant Biotechnologies in?

CollPlant Biotechnologies is in the Biotechnology industry

What country is CollPlant Biotechnologies based in?

CollPlant Biotechnologies is headquartered in Israel

When did CollPlant Biotechnologies go public?

CollPlant Biotechnologies's initial public offering (IPO) was on January 31, 2018

Is CollPlant Biotechnologies in the S&P 500?

No, CollPlant Biotechnologies is not included in the S&P 500 index

Is CollPlant Biotechnologies in the NASDAQ 100?

No, CollPlant Biotechnologies is not included in the NASDAQ 100 index

Is CollPlant Biotechnologies in the Dow Jones?

No, CollPlant Biotechnologies is not included in the Dow Jones index

When was CollPlant Biotechnologies's last earnings report?

CollPlant Biotechnologies's most recent earnings report was on Mar 26, 2025

When does CollPlant Biotechnologies report earnings?

The next expected earnings date for CollPlant Biotechnologies is May 29, 2025

Should I buy CollPlant Biotechnologies stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page